Cite
HARVARD Citation
van Vollenhoven, R. et al. (n.d.). THU0199 Tofacitinib, An Oral Janus Kinase Inhibitor, in The Treatment of Rheumatoid Arthritis: Changes in Lymphocytes and Lymphocyte Subset Counts and Reversibility after Up To 8 Years of Tofacitinib Treatment. Annals of the rheumatic diseases. p. 258. [Online].